Leonard Schleifer, Regeneron CEO (AP Images)

What hap­pens when the N-of-1 is the pres­i­dent of the US? Re­gen­eron is about to find out

Pres­i­dent Trump is tak­ing a very per­son­al in­ter­est in an­oth­er ex­per­i­men­tal drug for Covid-19.

Fri­day af­ter­noon, af­ter he had test­ed pos­i­tive for coro­n­avirus, the White House put out a state­ment say­ing that Trump had tak­en an 8 gram dose of Re­gen­eron’s an­ti­body cock­tail — the high dose that ap­peared to do bet­ter than the low dose in terms of bat­ting down vi­ral loads.

Right af­ter word ar­rived that Trump had tak­en the ex­per­i­men­tal ther­a­py, he was trans­ferred to Wal­ter Reed — news that im­me­di­ate­ly height­ened fears about his con­di­tion. The Wash­ing­ton Post not­ed that Trump and his team de­cid­ed to make the move while he could still walk.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.